February 19, 2010 (FinancialWire) — Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) said that Juliet Singh has resigned as president and chief executive officer of the company and as a director on its board. The Transdel board has appointed Jeffrey Abrams, company founder and current board member, as the chairman. It also named John Lomoro, the company’s chief financial officer, as acting CEO.

The Transdel board has initiated a search for a new CEO, according to a company statement. The statement also said that Singh has agreed to provide consulting services to the company.

California-based Transdel Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. The company’s cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.

Ketotransdel, the company’s lead pain product, has completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts anti-inflammatory and analgesic effects.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.